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vs. NT in 79%, 56%, and 36% of model runs, respectively.
CONCLUSIONS: For the management of BCBM patients, ZA
is the preferred bisphosphonate as it is more effective and less
expensive than other IV agents or even no therapy.
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OBJECTIVES: The primary core analysis of the BIG 1–98 study
showed that in postmenopausal women with hormone receptor
positive (HR+) early breast cancer, the aromatase inhibitor (AI)
letrozole (LET) signiﬁcantly reduced the risk of recurrence by
19% overall (95% CI 7–30%) and the risk of relapse in distant
sites by 27% overall (CI 12–40%) compared with tamoxifen
(TAM). Letrozole demonstrated non-signiﬁcant improvements in
overall survival and contralateral breast cancer. LET patients had
reduced risks of endometrial cancer and venous thromboem-
bolism (VTE), but increased risks of mild/moderate hypercho-
lesteraemia, cardiac events and fractures. This study reports the
cost-effectiveness of initial adjuvant therapy with LET vs. TAM
in postmenopausal women with HR+ early stage breast cancer
from the UK NHS perspective based on preliminary analyses of
published results of the BIG 1–98 trial. METHODS: A Markov
model describes the occurrence of contralateral tumours; locore-
gional recurrence; soft tissue, bone, and visceral metastases, and
treatment side effects (endometrial cancer, VTE, hip fractures,
other fractures, hypercholesterolaemia, and MI). Clinical para-
meters for TAM were based on published results of the BIG 1–98
trial and other published studies, as were health-state utilities.
Corresponding probabilities for LET were calculated by apply-
ing RRs for LET vs. TAM from the BIG 1–98 study. Costs of
breast-cancer care were estimated using UK patient-level
resource use data. Lifetime costs (2004UK£) and QALYs were
estimated for HR+ women aged 61 years at diagnosis, dis-
counted at 3.5% annually. RESULTS: Compared with TAM,
LET results in an additional 0.33 QALYs (12.84 vs. 12.51).
These beneﬁts are obtained at an additional cost of £4079
(£12,474 vs. £8395). Cost-effectiveness of LET vs. TAM is
£12,321 (95% CI £2672-£23,889) per QALY saved. CON-
CLUSION: Adjuvant treatment with letrozole is cost-effective
from a UK NHS perspective compared with tamoxifen and
should be considered in women diagnosed with HR+ early breast
cancer.
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OBJECTIVE: TS-1 is a newly developed oral anticancer drug.
We previously reported the treatment costs for gastric cancer in
Japan and suggested that TS-1 is cost saving compared to con-
ventional intravenous chemotherapy. The aim of this study is to
examine health utilities in gastric cancer patients and to assess
the cost-utility of TS-1. METHODS: Patients with advanced or
recurrent gastric cancer who were able to ingest meals were 
identiﬁed retrospectively from the ordering system database of
Showa University Hospital between January 1998 and July
2001. The utilities of the patients during chemotherapy were
assessed by oncology pharmacists on the basis of medical records
(including information on mobility, meal ingestion, pain, and
other symptoms), using the rating scale method, time trade-off
method, standard gamble method and EQ-5D mapping proce-
dure. The costs of the patients were calculated on the basis of
hospital billing data. Cost-utility analysis was conducted from a
societal perspective. RESULTS: Of the 23 patients who met the
inclusion criteria, 13 received TS-1 and 10 received conventional
intravenous chemotherapy. Mean (SD) utilities as measured by
the rating scale method, time trade-off method, standard gamble
method and EQ-5D mapping procedure were 0.89 (0.12), 0.90
(0.11), 0.94 (0.07), and 0.84 (0.18), respectively, in the TS-1
group. The corresponding utilities in the conventional intra-
venous chemotherapy group were 0.65 (0.18), 0.66 (0.18), 0.81
(0.12), and 0.52 (0.23), respectively. The utilities of the TS-1
were signiﬁcantly (P < 0.05) higher than those of conventional
intravenous chemotherapy by every technique. The mean
monthly cost during chemotherapy was signiﬁcantly lower in the
TS-1 group than in the conventionalintravenous chemotherapy
group (€2481 vs. €6458, P < 0.05). CONCLUSION: TS-1, an
oral anticancer agent, is a dominant strategy with a lower cost
and a greater health outcome than conventional intravenous
chemotherapy in patients with advanced or recurrent gastric
cancer.
PCN34
COST-EFFECTIVENESS OF ANASTROZOLE OVER TAMOXIFEN
IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST
CANCER FROM A UK NATIONAL HEALTH SERVICE
PERSPECTIVE: THE 5-YEAR COMPLETED TREATMENT
ANALYSIS OF THE ATAC TRIAL
Brown R1, Benedict A1, Mansel R2
1MedTap Institute at UBC, London, UK; 2University of Wales College
of Medicine, Cardiff, UK
OBJECTIVES: In the Arimidex, Tamoxifen Alone or in Combi-
nation (ATAC) trial, anastrozole produced signiﬁcantly longer
disease-free survival and time to recurrence compared with
tamoxifen in hormone receptor-positive (HR+) postmenopausal
women with early breast cancer after 5 years of treatment.
(ATAC Trialists’ Group. Lancet 2005;365:60–2) Based on these
ATAC results, the cost-utility of anastrozole versus tamoxifen is
estimated from the perspective of the UK National Health
Service (NHS). METHODS: A Markov model and Weibull sur-
vival curves ﬁtted to trial data were used to project 5-year out-
comes from the ATAC trial to an actuarial time point of 25 years.
Resource utilisation data were obtained primarily from a physi-
cian survey. Unit costs (2003–4 UK£) were obtained from routine
NHS sources. Utility scores for relevant health states were
obtained from 26 representative UK patients, using a standard
gamble technique. Costs and beneﬁts were discounted at the
annual rate of 3.5%. All effectiveness and cost parameters
subject to uncertainty were varied in a probabilistic analysis.
Incremental cost effectiveness ratios (ICERs), 95% CIs, and
acceptability curves were calculated. RESULTS: The estimated
25 year ICER of anastrozole compared with generic tamoxifen
was £7811 (£219–31,438) per QALY gained with a probability
of the order of 90% that it lies below £20,000 per QALY gained.
The results were sensitive to the time horizon of the model and
